-
摘要: 第39届欧洲泌尿外科协会(EAU)年会于2024年4月5日—8日在法国巴黎召开。来自全球各个国家和地区的泌尿外科医生齐聚,就肾细胞癌的多个临床热点进行了报道与讨论,本文就肾癌诊断、手术治疗、疾病预后及转移性肾癌的治疗等部分重点内容做简要介绍和归纳。Abstract: The 39th annual congress of the European Association of Urology(EAU) was held in Paris, France from April 5th to 8th, 2024. Urologists from various countries and regions around the world gathered to report and discuss a number of clinical hotspots of renal cell carcinoma. This article briefly introduced and summarized some key contents of kidney cancer, including diagnosis, surgical treatment, disease prognosis, and treatment of metastatic kidney cancer.
-
-
[1] Re C, Brembilla G, Pennella R, et al. Diagnostic performance of multiparametric magnetic resonance imaging before renal biopsy using Clear Cell Likelihood Score(ccLS)[C]. Paris: EAU24-39th Annual EAU Congress, 06 April 2024, EGPT 05.
[2] Dong W, Fang C. A MRI-based radiomics model for differentiation of benign and malignant small renal masses(≤4 cm)[C]. Paris: EAU24-39th Annual EAU Congress, 07 April 2024, Abstract session 20.
[3] Singh UP, Surekha S, Shukla A, et al. Diagnostic accuracy of 99mTc Sesta-MIBI SPECT/CT for preoperative differentiation of oncocytoma from renal cell carcinoma[C]. Paris: EAU24-39th Annual EAU Congress, 07 April 2024, Abstract session 20.
[4] Belladelli F, Re C, Cei F, et al. Renal biopsy does not affect mortality in renal mass patients when confronted with upfront surgery: A propensity score adjusted analysis[C]. Paris: EAU24-39th Annual EAU Congress, 06 April 2024, EGPT 05.
[5] Bernstein DE, Warren H, Santiapillai J, et al. The role of biopsy in small renal masses < 4 cm: A european modified delphi consensus statement[C]. Paris: EAU24-39th Annual EAU Congress, 07 April 2024, Abstract session 20.
[6] Nicolazzini M, Palumbo C, Abdulvagabov A, et al. Progression rates in prospective series of small renal masses treated with active surveillance according to the newly-proposed cT1a classification[C]. Paris: EAU24-39th Annual EAU Congress, 07 April 2024, Abstract session 20.
[7] Abdelaziz A, Bhandari M, Trecarten S, et al. Does the timing of intervention affect overall survival? A comparative study of early versus delayed interventions for small renal masses[C]. Paris: EAU24-39th Annual EAU Congress, 07 April 2024, Abstract session 20.
[8] Saitta C, Nguyen M, Capitanio U, et al. Comparative analysis of oncological and functional outcomes of radical and partial nephrectomy in pT3aN0M0 renal cell carcinoma: A multicenter propensity score-matched analysis[C]. Paris: EAU24-39th Annual EAU Congress, 08 April 2024, Abstract session 47.
[9] Pietersen PI, Stougaard S, Keeley FX, et al. Renal function after CT-guided cryoablation of small renal tumours in patients with solitary kidney: an analysis of European multinational prospective EuRECA registry[C]. Paris: EAU24-39th Annual EAU Congress, 07 April 2024, Abstract session 30.
[10] Naito H, Homare O, Ryou I, et al. Postoperative recurrence factors in patients with pT3N0M0 clear cell renal cell carcinoma, called the M0 intermediate-high-risk group of the KEYNOTE 564 trial[C]. Paris: EAU24-39th Annual EAU Congress, 06 April 2024, EGPT 05.
[11] Bedke J, Grünwald V, Müller-Huesmann H, et al. Prognostic factors for Overall Survival(OS)in patients receiving First-line(1 L)Nivolumab plus Ipilimumab(NIVO+IPI)for advanced/metastatic Renal Cell Carcinoma(aRCC)in a real-world setting in Germany[C]. Paris: EAU24-39th Annual EAU Congress, 08 April 2024, Abstract session 42.
[12] Mollica V, Massari F, Fiala O, et al. Papillary Renal Cell Carcinoma(pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors(TKIs)from the ARON-1 study[C]. Paris: EAU24-39th Annual EAU Congress, 08 April 2024, Abstract session 42.
[13] Finati M, Cirulli GO, Chiarelli G, et al. The role of cytoreductive nephrectomy in metastatic clear cell carcinoma: Analisys of an other-cause mortality matched population from the contemporary immunotherapy era[C]. Paris: EAU24-39th Annual EAU Congress, 08 April 2024, Abstract session 42.
-
计量
- 文章访问数: 317
- 施引文献: 0